Asset Details
Do you wish to reserve the book?
Therapeutic Potential of Bifidobacterium longum subsp. infantis B8762 on Gut and Respiratory Health in Infant
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapeutic Potential of Bifidobacterium longum subsp. infantis B8762 on Gut and Respiratory Health in Infant
Do you wish to request the book?
Therapeutic Potential of Bifidobacterium longum subsp. infantis B8762 on Gut and Respiratory Health in Infant
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapeutic Potential of Bifidobacterium longum subsp. infantis B8762 on Gut and Respiratory Health in Infant
2025
Overview
Respiratory tract and gastrointestinal infections in pediatric populations are major public health concerns. Addressing these challenges necessitates effective preventative and therapeutic strategies. This study assessed the efficacy of the probiotic Bifidobacterium longum subsp. infantis B8762 (0.5 × 1010 CFU) in reducing the duration and frequency of these infections in young children. In a randomized trial, 115 eligible children were assigned to either the probiotic (n = 57; 3.51 ± 0.48 months old) or placebo (n = 58; 2.78 ± 0.51 months old) group, with daily consumption for 4 weeks. The probiotic group demonstrated a lower duration of infections than the placebo group (p < 0.05). The probiotic group also showed fewer clinical visits due to respiratory and gastrointestinal problems as compared to the placebo group (p = 0.009 & p = 0.004, respectively). Oral swab samples revealed that the placebo group had higher levels of pro-inflammatory cytokine TNF-α after 4 weeks (p = 0.033), while the probiotic group demonstrated a balanced cytokine response, indicating modulation of the immune system. Genomic analysis showed that B8762 harbors various genes for the synthesis of proteins and vitamins crucial for the gut health of children. Both the clinical and genomic findings suggested that B8762 offered a therapeutic effect on gut and respiratory health in children, highlighting its potential in managing common pediatric infections.
Publisher
MDPI AG,MDPI
Subject
/ Analysis
/ Bifidobacterium longum subspecies infantis
/ Children
/ Diarrhea
/ Enzymes
/ Female
/ Gastrointestinal Tract - microbiology
/ Humans
/ Infant
/ Male
/ Probiotics - administration & dosage
/ Probiotics - therapeutic use
/ Proteins
/ Respiratory Tract Infections - microbiology
/ Respiratory Tract Infections - therapy
/ Viruses
